Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Li, Zhuang Hua ^a,b   Qiu, Miao Zhen ^a   Zeng, Zhao Lei ^a   Luo, Hui Yan ^a   Wu, Wen Jing ^a   Wang, Feng ^a   Wang, Zhi Qiang ^a   Zhang, Dong Sheng ^a   Li, Yu Hong ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b DONGGUAN PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; COPPER EXPORTING ADENOSINE TRIPHOSPHATASE; MESSENGER RNA; PLATINUM COMPLEX; SMALL INTERFERING RNA; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; ATP7A PROTEIN, HUMAN; CATION TRANSPORT PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL DESTRUCTION; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; COPPER TRANSPORTING P TYPE ADENOSINE TRIPHOSPHATASE GENE; FEMALE; GENE EXPRESSION SYSTEM; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TUMOR GENE; APOPTOSIS; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR SPACE; LUNG TUMOR; METABOLISM; PATHOLOGY; SURVIVAL; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS;

EID: 84856419116     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-21     Document Type: Article

References (25)

1. Rinaldi M, Cauchi C, Gridelli C. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 2006, 17(Suppl 5):v64-v67.
2. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31. 10.1016/j.critrevonc.2007.02.001, 17336087.
3. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14:1291-1295. 10.1158/1078-0432.CCR-07-2238, 18316546.
4. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999, 55:929-937.
5. Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, Howell SB. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 2004, 53:239-246. 10.1007/s00280-003-0736-3, 14648017.
6. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007, 26:71-83. 10.1007/s10555-007-9045-3, 17318448.
7. Setty SR, Tenza D, Sviderskaya EV, Bennett DC, Raposo G, Marks MS. Cell-specific ATP7A transport sustains copper-dependent tyrosinase activity in melanosomes. Nature 2008, 454:1142-1146. 10.1038/nature07163, 2812007, 18650808.
8. Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M, Takebayashi Y. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 2001, 8:1285-1287.
9. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000, 60:1312-1316.
10. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004, 10:4661-4669. 10.1158/1078-0432.CCR-04-0137, 15269138.
11. Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003, 9:5853-5859.
12. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005, 4:25. 10.1186/1476-4598-4-25, 1181826, 16033649.
13. Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF, Fu JH. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Reports 2009, 22:65-71.
14. Wang L, Sun J, Li YQ, Chen ZS, Akiyama S, Xian LJ. Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells. Anticancer Drugs 2007, 18:1015-1021. 10.1097/CAD.0b013e328223f14d, 17704651.
15. Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J, Song L. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res 2011, 17:3089-3099. 10.1158/1078-0432.CCR-10-3068, 21447726.
16. Afton SE, Caruso JA, Britigan BE, Qin Z. Copper egress is induced by PMA in human THP-1 monocytic cell line. Biometals 2009, 22:531-539. 10.1007/s10534-009-9210-y, 19205902.
17. Aida T, Takebayashi Y, Shimizu T, Okamura C, Higasimoto M, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Miyazaki K, et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol 2005, 97:41-45. 10.1016/j.ygyno.2004.12.042, 15790435.
18. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52:1855-1865. 10.1016/S0006-2952(97)81490-6, 8951344.
19. Ling V. Multidrug resistance and P-glycoprotein expression. Ann NY Acad Sci 1987, 507:7-8. 10.1111/j.1749-6632.1987.tb45786.x, 2894794.
20. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, et al. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion. J Invest Dermatol 2008, 128:957-971. 10.1038/sj.jid.5701082, 17943188.
21. Casale F, D'Angelo V, Addeo R, Caraglia M, Crisci S, Rondelli R, Di Tullio MT, Indolfi P. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 2004, 12:1201-1207.
22. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther 2011, 12:780-787. 10.4161/cbt.12.9.17781, 21892003.
23. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005, 53:3-11. 10.1016/j.critrevonc.2004.08.008, 15607931.
24. Allday MJ, Inman GJ, Crawford DH, Farrell PJ. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J 1995, 14:4994-5005. 394603, 7588628.
25. Plasencia C, Martinez-Balibrea E, Martinez-Cardus A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 2006, 29:225-235.